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Background: Nonalcoholic steatohepatitis (NASH) carries an increased risk of cardiovascular disease (CVD) relative
to the general population. We sought to evaluate whether differences in lipoprotein subfractions in obese patients
with and without NASH contributes to this difference in CVD risk.
Findings: Ion mobility analysis was performed on 78 individuals with obesity undergoing weight loss surgery.
All individuals had standard of care liver biopsies performed during surgery. Patients with NASH had significantly
smaller peak LDL diameter (P = 0.02, 219.0 Å vs. 222.6 Å), and levels of IDL2 (P = 0.01, 104. nmol/L vs. 133.4 nmol/L)
and HDL2b (P = 0.05, 676.7 nmol/L vs. 880.1 nmol/L) compared to those without NASH. NASH patients had
significantly higher LDL-IVb levels than those without NASH (P = 0.02, 49.0 nmol/L vs. 37.1 nmol/L).
The inverse association of LDL peak diameter with NASH remained significant after adjustment for diabetes
(P = 0.02). HDL2b levels were inversely correlated with hepatocyte ballooning and NASH and these remained
significant after adjustment for diabetes (P = 0.0017 and P = 0.007, respectively). IDL2 levels were inversely correlated
with NASH, hepatocyte ballooning and fibrosis stage but these were not significant after adjustment for diabetes.
Conclusions: The lipoprotein subfraction profile in subjects with NASH is characterized by small peak LDL diameter,
reduced HDL2b levels and elevated LDL-IVb levels. These changes may contribute to the increased CVD seen in
patients with NASH.
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Cardiovascular disease (CVD) is prevalent in individuals
with nonalcoholic fatty liver disease (NAFLD). Three com-
munity-based studies from the United States and Japan
have demonstrated an increased CVD risk in individuals
with radiographic evidence of NAFLD when compared to
those without NAFLD [1-3]. Individuals with histologi-
cally defined nonalcoholic steatohepatitis (NASH) have
also been shown to have an increased CVD mortality
when compared to the general population [4,5]. Thus,
individuals with both radiographic NAFLD and histologi-
cally defined NASH are at increased risk for CVD and
CVD-related mortality.
Multiple factors likely contribute to the increased
CVD risk seen in those with NASH including hyperinsu-
linemia, impaired thrombolysis and alterations in lipid* Correspondence: kcorey@partners.org
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unless otherwise stated.and lipoprotein metabolism. To date studies of lipids in
NASH have been largely limited to standard lipid pro-
files which include total cholesterol, triglycerides, high
density lipoproteins (HDL) cholesterol and a calculated,
rather than direct, measurement of low density lipopro-
tein (LDL) cholesterol. While these parameters are ac-
cepted markers of CVD risk, it has long been recognized
that these measures provide only a crude index of disease
pathophysiology and recent evidence shows that additional
information can be gained from measurements of lipopro-
tein particles and their subfractions [6-8].
Ion Mobility (IM) is an innovative method that uses
gas-phase differential electrophoretic macromolecular
mobility to distinguish lipoprotein particles as a function
of their size and to directly and rapidly quantify their
plasma levels [9,10]. We hypothesized that IM would
reveal important differences in the lipoprotein subfraction
profiles of individuals with obesity with and without
NASH that may contribute to the increased CVD seen
in NASH.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Corey et al. Lipids in Health and Disease 2014, 13:100 Page 2 of 4
http://www.lipidworld.com/content/13/1/100Methods
This cohort study included consecutively enrolled pa-
tients who underwent weight loss surgery (WLS) at the
Bon Secours Health System between 2010 and 2012.
Subjects were assessed by a treating clinician for weight,
height, BMI and co-morbidities. Diabetes mellitus was
defined by a fasting glucose ≥ 126 mg/dL, HbA1C >6.5%
or known diagnosis of diabetes. Hypertension was defined
by a blood pressure ≥135/85 or undergoing treatment for
hypertension. Individuals on lipid lowering therapy were
excluded. No individual experienced significant weight
loss prior to surgery.
All subjects undergoing WLS had a standard of care
liver biopsy at the time of surgery. Liver biopsies were
reviewed by single blinded hepatopathologist (JM) and
assigned a score for grade of steatosis (grade 0 = <5% stea-
tosis; 1 = 5-33%; 2 = 33-66%; 3 = >66%), hepatocyte bal-
looning (0 = no ballooning; 1 = few; 2 =many), and lobular
inflammation per 200 × (0 = no foci; 1 = <2 foci; 2 = 2–4
foci; 3 = >4 foci), as described by Kleiner et al. [11]
NAFLD activity score (NAS) is a sum of the scores for
steatosis grade, lobular inflammation and hepatocyte bal-
looning and ranges from 0–8. Fibrosis stage was assigned
according to the modified Brunt stage (stage 0, 1a, 1b, 1c,
2, 3, or 4) [11]. Non-NASH was defined by the presence
of grade 0 or greater not meeting criteria for NASH.
NASH was defined as lobular inflammation > =1, hepato-
cyte ballooning > =1 and steatosis grade > =1 [12].
Ion mobility analysis
IM was used on to directly quantify the full spectrum of
lipoprotein particles, from the smallest, densest HDL par-
ticles to large buoyant VLDL particles, in baseline plasma
samples as described previously.Table 1 Baseline characteristics
Non-NA






Mean BMI (SD) 46.8 (6
Obstructive sleep apnea, n (%) 23 (56
Diabetes mellitus, n (%) 10 (25
Mean insulin, μU/dL(SD) 32.4 (2
Mean high density lipoprotein, mg/dL (SD) 41.8 (7
Mean triglyceride level, mg/dL (SD) 108.9 (6
Mean low density lipoprotein, mg/dL (SD) 101.4 (3
Mean total cholesterol, mg/dL (SD) 165.0 (4Statistical analysis
All statistical analyses were performed using SAS software,
version V.9.2 (SAS Institute, Cary, NC). Continuous vari-
ables were analyzed using a Student’s t-test for normally
distributed variables and a Wilcoxon rank sum test for
variables that were not normally distributed. Categorical
variables were analyzed using a Chi square test or Fisher’s
exact test as appropriate. Multivariable logistic regression
modeling was used to assess the independent association
of OSA with histology.
This study was approved by the Partners’ Health Care
Human Research Committee.Results
Baseline characteristics
Seventy-eight individuals were included in this cohort.
Mean age was 45.6 years and mean BMI was 47.3 kg/m2.
Eighty-five percent of the patients were women, 78.2%
were white and 35.9% carried a diagnosis of diabetes
mellitus.Clinical characteristics of NASH and non-NASH patients
There were no differences in mean age or BMI in NASH
and non-NASH patients (Table 1). Diabetes mellitus and
hyperlipidemia were more prevalent in NASH patients
than in non-NASH patients (P = 0.03, 50.0% vs. 25% and
P = 0.02, 54.1% vs. 26.9%, respectively). Mean HDL chol-
esterol was lower in patients with NASH when compared
to those without NASH (P = 0.003, 36.5 vs. 41.8 mg/dL).
Both LDL cholesterol and total cholesterol were higher in
non-NASH patients (P = 0.007 and 0.009, respectively).
There were no significant differences in insulin or trigly-
ceride levels.SH Definite NASH P Value
1.9) 47.3 (13.3) 0.27
.2) 28 (79.7) 0.12
.7) 4 (10.8)
.3) 33 (89.2) 0.03
.4) 48.0 (7.3) 0.43
.1) 26 (67.6) 0.36
.0) 18 (50.0) 0.03
7.3) 32.3 (19.1) 0.98
.9) 36.5 (7.5) 0.003
9.9) 122.1 (73.0) 0.42
2.9) 81.7 (29.2) 0.007
0.6) 142.8 (31.7) 0.009
Table 2 Lipoprotein subfraction profiles in those with and
without NASH
Non-NASH Definite NASH P Value
LDL Peak Diameter, Å (SD) 222.6 (5.4) 219.0 (4.5) 0.02
LDL-IVb, nmol/L (SD) 37.1 (16.3) 49.0 (28.0) 0.02
HDL2b, nmol/L (SD) 880.1 (465.2) 676.6 (456.7) 0.05
IDL2, nmol/L (SD) 133.4 (60.8) 104.1 (38.6) 0.01
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LDL peak diameter was significantly smaller in NASH pa-
tients those without NASH (P = 0.02, 219.0 Å vs. 222.6 Å)
(Table 2). Notably, LDL peak diameter was inversely cor-
related with hepatocyte ballooning (P = 0.007), steatosis
grade (P = 0.022) and NAS (P = 0.015). When adjusted
for the presence of diabetes the inverse correlation
between LDL peak diameter and NAS remained signifi-
cant (P = 0.02) while the significance of the correlations
for hepatocyte ballooning and steatosis grade was reduced
(both P = 0.06).
In addition, very small LDL-IVb levels were signifi-
cantly higher in NASH patients than non-NASH patients
(P = 0.02, 49.0 nmol/L vs. 37.1 nmol/L), and were directly
correlated with hepatocyte ballooning (P = 0.03), steatosis
grade (P = 0.03) and NAS (P = 0.04). The correlation with
NASH remained significant after adjustment for diabetes
(P = 0.02).
NASH was also characterized by low HDL2b levels
when compared to non-NASH (P = 0.05, 676.7 nmol/L vs.
880.1 nmol/L). HDL2b levels were inversely correlated
to hepatocyte ballooning and NAS which remained
significant after adjustment for diabetes (P = 0.017 and
P = 0.007).
Mean IDL2 level was significantly lower in NASH pa-
tients than non-NASH patients (P = 0.01. 104.1 nmol/L vs.
133.4 nmol/L), and IDL2 levels were inversely correlated
with hepatocyte ballooning (P = 0.01), NAS (P = 0.05) and
fibrosis stage (P = 0.05). However, after adjustment for dia-
betes these correlations were not significant.
Lipoprotein particles in NASH and Non-NASH patient
without diabetes mellitus
When this analysis was restricted to individuals without
diabetes mellitus, LDL-IVb remained significantly higher
in those with NASH (p = 0.03) and IDL2 remained lower
(p = 0.03). LDL peak diameter and HDL2 remained lower
in NASH patients but these differences were not statisti-
cally significant.
Conclusions
The present study reveals several important novel dif-
ferences in the lipid profiles on patients with and
without NASH. Patients with NASH were found to have asignificantly smaller LDL peak diameter than those with-
out NASH. In addition, we found that LDL-IVb was
significantly higher in those with NASH. LDL-IVb is
the smallest subclass of LDL particles with a diameter
of 22.0-23.3 nm. LDL-IVb represents a relatively
minor subfraction of LDL, accounting for approxi-
mately 10% of LDL particles. However, a study by
Williams et al. found that LDL-IVb was the single
best predictor among lipoproteins of increased coron-
ary artery stenosis [13]. Stenosis change was six times
more rapid among individuals with LDL-IVb levels in
the highest quartile than those with the lowest LDL-IVb
levels. This study suggested that a considerable portion of
CVD risk attributed to small dense LDL may be driven by
very small LDL particles. Thus, our finding of increased
LDL-IVb levels in NASH patients may contribute to the
increased CVD experienced by this group.
HDL is composed of 5 subclasses including the small
in size HDL3a, HDL3b, HDL3c, as well as the large
HDL2a and HDL2b [13]. Decreased HDL2b content
relative to HDL3b and HDL3c is associated with an in-
creased CVD risk [14,15]. We found that, in individuals
with NASH, HDL2b was significantly lower in those
without NASH and it is possible that this is related to
the increased CVD seen in NASH.
Several important limitations in the present study
must be acknowledged. Our group included all individ-
uals undergoing weight loss surgery and thus the find-
ings may not be generalizable to the full spectrum of
NAFLD and NASH patients. Finally, our study is limited
by small size and predominance of white women. Future
studies of increased size and diversity as well as evalu-
ation of lipoprotein particle differences in patients with
normal liver histology compared to those with steatosis
and NASH are needed.
In conclusion, the present study suggests that individ-
uals with NASH may have a more atherogenic lipopro-
tein subfraction profile than those without fatty liver
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• Nonalcoholic steatohepatitis (NASH) is associated with atherogenic
dyslipidemia.
• The dyslipidemia of NASH is characterized by small peak LDL diameter and
elevated levels of LDL-IVb.
• NASH is also associated with low levels of IDL2 and HDL2.
• These differences may contribute to the increased cardiovascular disease
prevalence seen in individuals with NASH.
Research questions
• Does the dyslipidemia result from NASH or contribute to the development
of NASH?
• Does the atherogenic dyslipidemia seen with NASH improve with NASH
treatment?
• How does therapy with lipid lowering agents impact this dyslipidemia
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